Drug profile · INN
solriamfetol
SUNOSI
solriamfetol (SUNOSI) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.
Drug details — solriamfetol
- US status
- approved
- Class
- Nervous system (N06)
- Route
- —
- Patents
- 20
- Programs
- 14
- Data quality
- 0.83
Quick answer
solriamfetol (SUNOSI) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12318362
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 12263145
Methods of administering solriamfetol to lactating women
granted -
US 12194016
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 12102609
Methods of administering solriamfetol to lactating women
granted -
US 12090126
Methods of administering solriamfetol to lactating women
granted -
US 12064411
Methods of administering solriamfetol to lactating women
granted -
US 12036194
Methods of administering solriamfetol to lactating women
granted -
US 12005036
Methods of administering solriamfetol to lactating women
granted -
US 11986455
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11986454
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11969404
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11872204
Methods of administering solriamfetol to lactating women
granted -
US 11872203
Methods of administering solriamfetol to lactating women
granted -
US 11857528
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11850226
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11850228
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11850227
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11839599
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11839598
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11793776
Methods of administering solriamfetol to lactating women
granted
Frequently asked questions
What is solriamfetol?
solriamfetol (SUNOSI) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.
What is the brand name for solriamfetol?
SUNOSI is a marketed brand name for solriamfetol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of solriamfetol?
solriamfetol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.